Next Article in Journal
The Role of Hydrogen Peroxide in Redox-Dependent Signaling: Homeostatic and Pathological Responses in Mammalian Cells
Next Article in Special Issue
Adoptive T Cell Therapy Strategies for Viral Infections in Patients Receiving Haematopoietic Stem Cell Transplantation
Previous Article in Journal
The Interplay among PINK1/PARKIN/Dj-1 Network during Mitochondrial Quality Control in Cancer Biology: Protein Interaction Analysis
Previous Article in Special Issue
Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site

Allogeneic CAR-T Cells: More than Ease of Access?

Department of Haematological Medicine, King’s College London, London SE5 9NU, UK
Department of Haematology, King’s College Hospital NHS Foundation Trust, London SE5 9RS, UK
Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, University of Sussex, Falmer BN1 9PX, UK
Authors to whom correspondence should be addressed.
Cells 2018, 7(10), 155;
Received: 10 September 2018 / Revised: 27 September 2018 / Accepted: 27 September 2018 / Published: 1 October 2018
(This article belongs to the Special Issue Emerging Cellular Therapies: T Cells and Beyond)
Patient derived anti-CD19 chimeric antigen receptor-T (CAR-T) cells are a powerful tool in achieving a complete remission in a range of B-cell malignancies, most notably B-acute lymphoblastic leukaemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL). However, there are limitations, including inability to manufacture CAR-T cells from the patient’s own T cells, disease progression and death prior to return of engineered cells. T cell dysfunction is known to occur in cancer patients, and several groups have recently described differences in CAR-T cells generated from chronic lymphocytic leukaemia (CLL) patients compared with those from a healthy donor. This is thought to contribute to the low response rate in this disease group. Healthy donor, gene-edited CAR-T cells which do not require human leucocyte antigen (HLA) matching have the potential to provide an ‘off the shelf’ product, overcoming the manufacturing difficulties of producing CAR-T cells for each individual patient. They may also provide a more functional, potent product for malignancies such as CLL, where T cell dysfunction is common and frequently cannot be fully reversed during the manufacturing process. Here we review the potential benefits and obstacles for healthy donor, allogeneic CAR-T cells. View Full-Text
Keywords: CAR-T cells; cancer immunotherapy; gene editing CAR-T cells; cancer immunotherapy; gene editing
Show Figures

Figure 1

MDPI and ACS Style

Graham, C.; Jozwik, A.; Pepper, A.; Benjamin, R. Allogeneic CAR-T Cells: More than Ease of Access? Cells 2018, 7, 155.

AMA Style

Graham C, Jozwik A, Pepper A, Benjamin R. Allogeneic CAR-T Cells: More than Ease of Access? Cells. 2018; 7(10):155.

Chicago/Turabian Style

Graham, Charlotte, Agnieszka Jozwik, Andrea Pepper, and Reuben Benjamin. 2018. "Allogeneic CAR-T Cells: More than Ease of Access?" Cells 7, no. 10: 155.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop